Page last updated: 2024-12-11
am 555s
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
TAC 101: inhibits liver metastasis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9800306 |
| CHEMBL ID | 32994 |
| SCHEMBL ID | 1133175 |
| MeSH ID | M0291321 |
Synonyms (35)
| Synonym |
|---|
| 125973-56-0 |
| amsilarotene |
| tac-101 |
| am-555s |
| 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid |
| CHEMBL32994 |
| 4-(3,5-bis(trimethylsilyl)benzamido)benzoic acid |
| am555s |
| benzoic acid, 4-((3,5-bis(trimethylsilyl)benzoyl)amino)- |
| q1418f39mh , |
| ccris 9419 |
| 4-(3,5-bis(trimethylsilyl)benzamido) benzoic acid |
| amsilarotene [inn] |
| unii-q1418f39mh |
| tac 101 |
| am 555s |
| tac101 |
| amsilarotene [who-dd] |
| SCHEMBL1133175 |
| am555s,tac-101 |
| DTXSID90155013 |
| EX-A128 |
| AKOS032947226 |
| BCP06502 |
| FT-0769431 |
| amsilarotene; tac 101 |
| benzoic acid, 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]- |
| Q27286879 |
| MS-26360 |
| 4-[3,5-bis(trimethylsilyl) benzamido] benzoic acid |
| 5-(4-methylphenyl)furan-2-carboxylicacidmethylester |
| HY-14653 |
| CS-0003504 |
| c20h27no3si2 |
| AC-36797 |
Research Excerpts
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " No autoinduction of metabolism was observed with dosing over 28 days." | ( Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. Brenckman, WD; Hawkins, MJ; Hong, WK; Jacobs, H; Kessler, C; Kurie, JM; Lee, JS; Marshall, JL; Ness, E; Petros, W; Rizvi, NA, 2002) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID82341 | Relative activity against human promyelocytic leukemia HL-60 cells. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60. |
| AID82163 | Ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes. | 1990 | Journal of medicinal chemistry, May, Volume: 33, Issue:5 | Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (21)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (42.86) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 10.89
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.89) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (11.54%) | 5.53% |
| Reviews | 1 (3.85%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (84.62%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||